A prospective, randomized, double-blind, comparative clinical study of efficacy and safety of a biosimilar adalimumab with innovator product in patients with active rheumatoid arthritis on a stable dose of methotrexate

Indian Journal of Rheumatology

Volumn 13, Issue 2, 2018, Pages 84-89

  Apsangikar, Prasad ^a   Chaudhry, Sunil ^a   Naik, Manoj ^a   Deoghare, Shashank ^a   Joseph, Jamila ^a  

^a RELIANCE LIFE SCIENCES PVT LTD   (India)

Author keywords

American College of Rheumatology; biosimilar; biosimilar adalimumab; double blind; reference adalimumab; rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ADALIREL; C REACTIVE PROTEIN; METHOTREXATE; RHEUMATOID FACTOR;

ADULT; ARTICLE; ASPIRATION PNEUMONIA; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DAS28; DOUBLE BLIND PROCEDURE; DRUG FATALITY; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART DISEASE; HUMAN; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; INFESTATION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SEPSIS; TREATMENT RESPONSE; UPPER GASTROINTESTINAL BLEEDING; URINARY TRACT INFECTION;

EID: 85047512537     PISSN: 09733698     EISSN: None     Source Type: Journal    
DOI: 10.4103/0973-3698.233164     Document Type: Article

References (12)

1. Ogrendik M. Rheumatoid arthritis is an autoimmune disease caused by periodontal pathogens. Int J Gen Med 2013;6:383-6.
2. Handa R, Rao UR, Lewis JF, Rambhad G, Shiff S, Ghia CJ, et al. Literature review of rheumatoid arthritis in India. Int J Rheum Dis 2016;19:440-51.
3. Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study. Ann Rheum Dis 2017;76:1679-87.
4. Heiberg MS, Rødevand E, Mikkelsen K, Kaufmann C, Didriksen A, Mowinckel P, et al. Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: Results from a 6-month longitudinal, observational, multicentre study. Ann Rheum Dis 2006;65:1379-83.
5. Dörner T, Kay J. Biosimilars in rheumatology: Current perspectives and lessons learnt. Nat Rev Rheumatol 2015;11:713-24.
6. Singh JA, Saag KG, Bridges SL Jr., Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1-26.
7. Keystone EC, van der Heijde D, Kavanaugh A, Kupper H, Liu S, Guérette B, et al. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: Final 10-year data in longstanding rheumatoid arthritis. J Rheumatol 2013;40:1487-97.
8. Ito Y, Hozumi K, Okada Y, Kurimoto S. Adalimumab with methotrexate in treatment-naïve Japanese patients with rheumatoid arthritis at risk of progressive structural joint damage: A Postmarketing Observational Study. Rheumatol Ther 2017;4:151-66.
9. Grazio S. Adalimumab (Humira)-Efficacy in rheumatoid arthritis treatment with particular reference to working ability. Reumatizam 2008;55:62-7.
10. Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits 2013;6:469-78.
11. Smolen JS, Aletaha D, Keystone E. Superior efficacy of combination therapy for rheumatoid arthritis: Fact or fiction? Arthritis Rheum 2005;52:2975-83.
12. Jani RH, Gupta R, Bhatia G, Rathi G, Ashok Kumar P, Sharma R, et al. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis 2016;19:1157-68.